Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | PIM1 | P11309 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12008746 | 0.90 | ALDH1A1 (0.62) | ALDH1A1LMNAMAPTFFAR1KMT2A | |
| SCHEMBL18539159 | 0.82 | CA9 (0.57) | NPC1ALDH1A1KDM4ELMNAMAPT | |
| SCHEMBL18539147 | 0.81 | NPC1 (0.66) | NPC1ALDH1A1KDM4EHPGDMAPT | |
| SCHEMBL12008725 | 0.78 | ALDH1A1 (0.69) | NPC1ALDH1A1LMNAMAPTKMT2A | |
| SCHEMBL20534357 | 0.73 | AKR1B1 (0.78) | MAPT | |
| SCHEMBL20534356 | 0.73 | AKR1B1 (0.78) | MAPT | |
| SCHEMBL12008718 | 0.73 | MEN1 (0.65) | NPC1ALDH1A1LMNAMAPTKMT2A | |
| SCHEMBL12008713 | 0.72 | POLB (0.62) | ALDH1A1LMNAMAPTFFAR1KMT2A | |
| SCHEMBL12008477 | 0.72 | NPC1 (0.79) | NPC1MAPTKMT2AMEN1 | |
| SCHEMBL12008766 | 0.69 | FFAR1 (0.86) | NPC1ALDH1A1KDM4ELMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170049751-A1 | OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF | DASGUPTA RAMANUJ (US) | 2017-02-23 | — | — | US | disclosed |
| US-20170049751-A1 | OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF | DASGUPTA RAMANUJ (US) | 2017-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170049751-A1 | OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF | CTNNB1, CTNNA1, CTNNBL1 | NPC1 1604/4885ALDH1A1 413/4885KDM4E 3915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.